Vertex Pharma (VRTX) Tops Q3 EPS by 39c; Raises Revenue Outlook

Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.01, $0.39 better than the analyst estimate of $3.62. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.22 billion.

GUIDANCE:

Vertex Pharma sees FY2022 revenue of $8.8-8.9 billion, versus the prior of $8.6-$8.8 billion and the consensus of $8.77 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary